Sirolimus-Based Immunosuppression Is Associated with Decreased Incidence of Post-Transplant Lymphoproliferative Disorder after Heart Transplantation: A Double-Center Study

Mammalian target of rapamycin (mTOR) inhibitors have been shown to reduce proliferation of lymphoid cells; thus, their use for immunosuppression after heart transplantation (HT) may reduce post-transplant lymphoproliferative disorder (PTLD) risk. This study sought to investigate whether the sirolimu...

Descripción completa

Detalles Bibliográficos
Autores principales: Asleh, Rabea, Vucicevic, Darko, Petterson, Tanya M., Kremers, Walter K., Pereira, Naveen L., Daly, Richard C., Edwards, Brooks S., Steidley, D. Eric, Scott, Robert L., Kushwaha, Sudhir S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8779206/
https://www.ncbi.nlm.nih.gov/pubmed/35054016
http://dx.doi.org/10.3390/jcm11020322

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8779206/
https://www.ncbi.nlm.nih.gov/pubmed/35054016
http://dx.doi.org/10.3390/jcm11020322

Ejemplares similares